Head-To-Head Contrast: NeuroMetrix (NASDAQ:NURO) versus Biotricity (NASDAQ:BTCY)

Biotricity (NASDAQ:BTCY) and NeuroMetrix (NASDAQ:NURO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Biotricity and NeuroMetrix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	1	0	0	2.00
NeuroMetrix	0	0	0	0	0.00

Valuation and Earnings

This table compares Biotricity and NeuroMetrix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06 million	0.83	-$14.09 million	($1.08)	-0.37
NeuroMetrix	$3.03 million	3.09	-$6.53 million	($4.59)	-0.99

NeuroMetrix has lower revenue, but higher earnings than Biotricity. NeuroMetrix is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biotricity and NeuroMetrix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
NeuroMetrix	-203.71%	-42.56%	-39.26%

Volatility & Risk

Biotricity has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.

Institutional & Insider Ownership

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 19.4% of NeuroMetrix shares are owned by institutional investors. 10.1% of Biotricity shares are owned by insiders. Comparatively, 7.3% of NeuroMetrix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Biotricity beats NeuroMetrix on 7 of the 12 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About NeuroMetrix

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.